ID   Ma-Mel-39a
AC   CVCL_A175
SY   Ma-Mel_39a; Ma-Mel-39A; Ma-Mel 39a; MaMel39a
DR   cancercelllines; CVCL_A175
DR   Cosmic; 1467755
DR   Cosmic; 1846620
DR   Cosmic; 2163855
DR   Cosmic; 2686404
DR   ECACC; 13012489
DR   ESTDAB; ESTDAB-172
DR   GEO; GSM109063
DR   GEO; GSM437006
DR   IGRhCellID; MaMel39a
DR   Progenetix; CVCL_A175
DR   Wikidata; Q54903793
RX   PubMed=16827748;
RX   PubMed=17311103;
RX   PubMed=20544847;
RX   PubMed=23348503;
RX   PubMed=23851445;
CC   Sequence variation: Mutation; HGNC; HGNC:1773; CDK4; Simple; p.Arg24His (c.71G>A); ClinVar=VCV000016929; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
ST   Source(s): ECACC=13012489; ESTDAB=ESTDAB-172
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 9
ST   D16S539: 13
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 10
ST   FGA: 21,22
ST   TH01: 6,8
ST   TPOX: 8,9
ST   vWA: 17,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   57Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 23
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=17311103; DOI=10.1371/journal.pone.0000236; PMCID=PMC1794595;
RA   Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A.,
RA   Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R.,
RA   Schadendorf D.;
RT   "B-RAF and N-RAS mutations are preserved during short time in vitro
RT   propagation and differentially impact prognosis.";
RL   PLoS ONE 2:E236-E236(2007).
//
RX   PubMed=20544847; DOI=10.1002/gcc.20785;
RA   Gast A., Scherer D., Chen B.-W., Bloethner S., Melchert S., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Somatic alterations in the melanoma genome: a high-resolution
RT   array-based comparative genomic hybridization study.";
RL   Genes Chromosomes Cancer 49:733-745(2010).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//